Daniel Sierra-Lara Martínez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Daniel Sierra-Lara Martínez has a total of 149 co-authors. Here are the top co-authors by number of shared publications:
- Alexandra Arias-Mendoza
Coronary Care Unit, National Institute of Cardiology, Mexico City, Mexico (A.A.-M.).
11 shared publications - Rodrigo Gopar-Nieto
Coronary Care Unit, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico
10 shared publications - Héctor González-Pacheco
Coronary Care Unit, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico
9 shared publications - Diego Araiza-Garaygordobil
Unidad de Cuidados Coronarios, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico
8 shared publications - Braiana Ángeles Díaz-Herrera
Coronary Care Unit Department, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico
5 shared publications - Amada Álvarez-Sangabriel
Instituto Nacional de Cardiología
3 shared publications
Latest Publications
- Open Access
- 30 September 2026
- Published by Oxford University Press (OUP) in European Heart Journal Open
- Vol. 6 (6)
OVER-TIME II trial: design and rationale of a multicentre randomized study evaluating antithrombotic strategies in patients with acute coronary syndrome and coronary artery ectasia
Introduction: Coronary artery ectasia (CAE) is characterized by diffuse coronary dilatation and increased thrombotic risk. In patients with acute coronary syndrome (ACS) and CAE, the optimal antithrombotic strategy remains unclear. Previously, an exploratory trial suggested that the combination of antiplatelet monotherapy plus oral anticoagulation may reduce ischaemic events without increasing bleeding risk compared to dual antiplatelet therapy (DAPT), although it was underpowered for definitive conclusions. Aims: The aim of this study is to evaluate the efficacy and safety of antiplatelet monotherapy plus direct oral anticoagulation compared with DAPT in patients with ACS and culprit-vessel CAE in a multicentre randomized setting. Methods and results: OVER-TIME II is a multicentre, multinational, randomized, open-label clinical trial with 1:1 allocation comparing acetylsalicylic acid 100 mg plus clopidogrel 75 mg vs. clopidogrel 75 mg plus rivaroxaban 15 mg daily. The study will include 326 patients with ACS and culprit-vessel CAE. Patients will be followed for 12 months. The co-primary efficacy endpoint is the time to first occurrence of a composite of cardiovascular death, non-fatal myocardial infarction, or repeat revascularization. The co-primary safety endpoint is the time to first occurrence of major or minor bleeding defined by the Bleeding Academic Research Consortium criteria. Secondary endpoints include individual components of the primary outcomes. Exploratory analyses will include genomic and transcriptomic profiling through DNA and RNA sampling to identify molecular signatures associated with thrombotic risk, treatment response, and clinical outcomes. Conclusion: OVER-TIME II is designed to provide robust multicentre randomized evidence regarding the efficacy and safety of an anticoagulation-based strategy in patients with ACS and CAE, with the potential to contribute to future clinical research and guideline development. Registration: NCT07511257. The trial is registered and publicly available on ClinicalTrials.gov and is currently actively recruiting patients.
- 30 September 2026
- Published by Oxford University Press (OUP) in European Heart Journal Open
- Vol. 6 (6)
Open AccessOVER-TIME II trial: design and rationale of a multicentre randomized study evaluating antithrombotic strategies in patients with acute coronary syndrome and coronary artery ectasia
Introduction: Coronary artery ectasia (CAE) is characterized by diffuse coronary dilatation and increased thrombotic risk. In patients with acute coronary syndrome (ACS) and CAE, the optimal antithrombotic strategy remains unclear. Previously, an exploratory trial suggested that the combination of antiplatelet monotherapy plus oral anticoagulation may reduce ischaemic events without increasing bleeding risk compared to dual antiplatelet therapy (DAPT), although it was underpowered for definitive conclusions. Aims: The aim of this study is to evaluate the efficacy and safety of antiplatelet monotherapy plus direct oral anticoagulation compared with DAPT in patients with ACS and culprit-vessel CAE in a multicentre randomized setting. Methods and results: OVER-TIME II is a multicentre, multinational, randomized, open-label clinical trial with 1:1 allocation comparing acetylsalicylic acid 100 mg plus clopidogrel 75 mg vs. clopidogrel 75 mg plus rivaroxaban 15 mg daily. The study will include 326 patients with ACS and culprit-vessel CAE. Patients will be followed for 12 months. The co-primary efficacy endpoint is the time to first occurrence of a composite of cardiovascular death, non-fatal myocardial infarction, or repeat revascularization. The co-primary safety endpoint is the time to first occurrence of major or minor bleeding defined by the Bleeding Academic Research Consortium criteria. Secondary endpoints include individual components of the primary outcomes. Exploratory analyses will include genomic and transcriptomic profiling through DNA and RNA sampling to identify molecular signatures associated with thrombotic risk, treatment response, and clinical outcomes. Conclusion: OVER-TIME II is designed to provide robust multicentre randomized evidence regarding the efficacy and safety of an anticoagulation-based strategy in patients with ACS and CAE, with the potential to contribute to future clinical research and guideline development. Registration: NCT07511257. The trial is registered and publicly available on ClinicalTrials.gov and is currently actively recruiting patients.
- Open Access
- 27 May 2026
- Published by Elsevier in JACC: Advances
- Vol. 5 (5) , 102752
Venous Excess Ultrasound Score and Acute Kidney Injury in Patients With Acute Heart Failure
- 27 May 2026
- Published by Elsevier in JACC: Advances
- Vol. 5 (5) , 102752
Open AccessVenous Excess Ultrasound Score and Acute Kidney Injury in Patients With Acute Heart Failure
- Open Access
- 14 January 2026
- Published by MDPI AG in Preprints.org
Dysregulation of the MEG3–ATF4 Axis in ST-Segment Elevation Myocardial Infarction: A Proof-of-Concept Study
Background/Objectives: Cardiovascular disease is the leading cause of morbidity and mortality worldwide, of which the myocardial Infarction is the most prevalent. However, the underlying pathophysiological mechanisms remain incompletely understood, but are tightly regulated by several cellular mechanisms, including long-non-coding. This study aimed to determine if MEG3 and ATF4 are involved in this pathology. Methods: A cross-section study was conducted at the Instituto Nacional de Cardiología Ignacio Chávez, patients with first time diagnosis STEMI and hemodynamic stability were categorized into with and without major adverse cardiovascular events, the most important clinical and biochemical parameters were collected, which were analyzed and subsequently correlated with MEG3 and ATF4. Results: Forty-two patients with a median age of 54 years (86% men) were included and classified with and without MACE. The expression of MEG3 in MACE group and No MACE (0.8974, 0.4186–1.4131 vs. 1.2259, 0.5516–2.3964; p = 0.0342), and ATF4 in MACE group and No MACE (2.8950, 0.7559–4.3287 vs. 2.3498, 1.0821–3.6903; p = 0.0396), ROC curve MEG3 showed an AUC of 0.6490 (0.4760 to 0.8221; p = 0.0924), in contrast ATF4 demonstrated an AUC of 0.7127 (0.5862 to 0.8393; p = 0.0107). Finally, correlation analyses revealed MEG3 was associated with CK-MB (r = 0.3978, 0.0630 to 0.6520; p = 0.0219), and ATF4 was correlated cTnT (r = 0.3328, 0.0284 to 0.5810; p = 0.0335) and with LVEF (r = –0.4283, –0.6503 to –0.1390; p = 0.0052). Conclusions: The dysregulation of MEG3 and transcription factor ATF4 are involved in pathophysiological mechanisms.
- 14 January 2026
- Published by MDPI AG in Preprints.org
Open AccessDysregulation of the MEG3–ATF4 Axis in ST-Segment Elevation Myocardial Infarction: A Proof-of-Concept Study
Background/Objectives: Cardiovascular disease is the leading cause of morbidity and mortality worldwide, of which the myocardial Infarction is the most prevalent. However, the underlying pathophysiological mechanisms remain incompletely understood, but are tightly regulated by several cellular mechanisms, including long-non-coding. This study aimed to determine if MEG3 and ATF4 are involved in this pathology. Methods: A cross-section study was conducted at the Instituto Nacional de Cardiología Ignacio Chávez, patients with first time diagnosis STEMI and hemodynamic stability were categorized into with and without major adverse cardiovascular events, the most important clinical and biochemical parameters were collected, which were analyzed and subsequently correlated with MEG3 and ATF4. Results: Forty-two patients with a median age of 54 years (86% men) were included and classified with and without MACE. The expression of MEG3 in MACE group and No MACE (0.8974, 0.4186–1.4131 vs. 1.2259, 0.5516–2.3964; p = 0.0342), and ATF4 in MACE group and No MACE (2.8950, 0.7559–4.3287 vs. 2.3498, 1.0821–3.6903; p = 0.0396), ROC curve MEG3 showed an AUC of 0.6490 (0.4760 to 0.8221; p = 0.0924), in contrast ATF4 demonstrated an AUC of 0.7127 (0.5862 to 0.8393; p = 0.0107). Finally, correlation analyses revealed MEG3 was associated with CK-MB (r = 0.3978, 0.0630 to 0.6520; p = 0.0219), and ATF4 was correlated cTnT (r = 0.3328, 0.0284 to 0.5810; p = 0.0335) and with LVEF (r = –0.4283, –0.6503 to –0.1390; p = 0.0052). Conclusions: The dysregulation of MEG3 and transcription factor ATF4 are involved in pathophysiological mechanisms.
- Open Access
- 2 January 2026
- Published by Ubiquity Press, Ltd. in Annals of Global Health
- Vol. 92 (1) , 111
Integrated Cardiovascular–Kidney–Metabolic Disease Burden in Mexico: Trends from 2000 to 2023 and Projections to 2050
Background: Cardiovascular–kidney–metabolic (CKM)‑related diseases are interconnected, yet their collective burden in Mexico remains unquantified. Objective(s): To quantify the magnitude, composition, temporal trends, geographic divergence, and projected trajectory of CKM‑related disease burden in Mexico. Methods: We analyzed Global Burden of Disease 2023 estimates of CKM‑related burden among Mexican adults aged 20 years or older; standard all‑age age‑standardized rates were used for comparisons with Latin America and the Caribbean and globally. Mutually exclusive causes were grouped into cardiovascular, kidney, type 2 diabetes, and metabolic dysfunction‑associated steatotic liver disease domains. We quantified disability‑adjusted life‑years (DALYs) during 2000–2023 and used 1990–2023 time series to project absolute burden and age‑standardized rates to 2050. Findings: CKM‑related DALYs increased from 3.82 million in 2000 to 8.71 million in 2023 (128%), and their share of all‑cause DALYs rose from 20.2% to 25.0%. In 2023, premature mortality accounted for 76.8% of the burden; cardiovascular disease and type 2 diabetes together accounted for 88.4%, with diabetes predominating among adults aged 40–64 years. Mexico’s age‑standardized DALY rate increased by 2.9% during 2000–2023, whereas rates declined by 16.1% in Latin America and the Caribbean and by 24.1% globally. Absolute DALYs are projected to reach 21.40 million by 2050 (95% prediction interval 19.27–23.77), while the age‑standardized rate remains broadly unchanged. Conclusions: Mexico has diverged from declining regional and global trends in age‑standardized CKM‑related burden. Persistent premature mortality, substantial diabetes burden during working age, and projected growth in absolute health loss support accelerated, coordinated public health and health‑system action across the CKM continuum.
- 2 January 2026
- Published by Ubiquity Press, Ltd. in Annals of Global Health
- Vol. 92 (1) , 111
Open AccessIntegrated Cardiovascular–Kidney–Metabolic Disease Burden in Mexico: Trends from 2000 to 2023 and Projections to 2050
Background: Cardiovascular–kidney–metabolic (CKM)‑related diseases are interconnected, yet their collective burden in Mexico remains unquantified. Objective(s): To quantify the magnitude, composition, temporal trends, geographic divergence, and projected trajectory of CKM‑related disease burden in Mexico. Methods: We analyzed Global Burden of Disease 2023 estimates of CKM‑related burden among Mexican adults aged 20 years or older; standard all‑age age‑standardized rates were used for comparisons with Latin America and the Caribbean and globally. Mutually exclusive causes were grouped into cardiovascular, kidney, type 2 diabetes, and metabolic dysfunction‑associated steatotic liver disease domains. We quantified disability‑adjusted life‑years (DALYs) during 2000–2023 and used 1990–2023 time series to project absolute burden and age‑standardized rates to 2050. Findings: CKM‑related DALYs increased from 3.82 million in 2000 to 8.71 million in 2023 (128%), and their share of all‑cause DALYs rose from 20.2% to 25.0%. In 2023, premature mortality accounted for 76.8% of the burden; cardiovascular disease and type 2 diabetes together accounted for 88.4%, with diabetes predominating among adults aged 40–64 years. Mexico’s age‑standardized DALY rate increased by 2.9% during 2000–2023, whereas rates declined by 16.1% in Latin America and the Caribbean and by 24.1% globally. Absolute DALYs are projected to reach 21.40 million by 2050 (95% prediction interval 19.27–23.77), while the age‑standardized rate remains broadly unchanged. Conclusions: Mexico has diverged from declining regional and global trends in age‑standardized CKM‑related burden. Persistent premature mortality, substantial diabetes burden during working age, and projected growth in absolute health loss support accelerated, coordinated public health and health‑system action across the CKM continuum.
- Open Access
- 24 September 2025
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 40 (3) , 1021-1033
Anticoagulant versus Antiplatelet Therapy After Acute Coronary Syndromes in Patients with Coronary Artery Ectasia: A Retrospective Cohort Study
Purpose: Patients with coronary ectasia (CAE) have an increased risk of major cardiovascular events (MACE). Current preventive treatments are uncertain, with oral anticoagulants often prescribed based on limited retrospective studies. Our aim is to help address the question: what is the most appropriate treatment? Methods: Using a retrospective cohort of patients with an ACS and CAE in a single center in Mexico City, two groups were observed based on the treatment at discharge: dual antiplatelet therapy (group 1) and anticoagulation with either a VKA or a DOAC, regardless of antiplatelet therapy (group 2). The main outcome was MACE, which was a composite of all-cause mortality, reinfarction, and ischemic stroke at 4.5 years follow-up. Results: A total of 354 patients admitted for ACS and CAE were included. 228 (64.4%) patients were classified in the DAPT group and 126 (35.5%) in the anticoagulants group. The DAPT group had higher type 2 diabetes rates, NSTEMI presentation, and lower-grade ectasia. The anticoagulation group had higher STEMI presentation and higher-grade ectasia. The DAPT group had 33 (14.5%) events of MACE, whereas the anticoagulation group had 16 (13.1%) events. Anticoagulants were not associated with a risk reduction of the primary endpoint (HR 0.95; 95% CI, 0.47–1.54; p = 0.59), nor any of the individual components. Conclusion: This retrospective cohort study showed similar effectiveness between DAPT and anticoagulation in patients with ACS and CAE for preventing MACE, and lower bleeding risk. Further research is needed to identify optimal candidates for each antithrombotic regime. Graphical DAPT: double antiplatelet therapy, HR: hazard ratio
- 24 September 2025
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 40 (3) , 1021-1033
Open AccessAnticoagulant versus Antiplatelet Therapy After Acute Coronary Syndromes in Patients with Coronary Artery Ectasia: A Retrospective Cohort Study
Purpose: Patients with coronary ectasia (CAE) have an increased risk of major cardiovascular events (MACE). Current preventive treatments are uncertain, with oral anticoagulants often prescribed based on limited retrospective studies. Our aim is to help address the question: what is the most appropriate treatment? Methods: Using a retrospective cohort of patients with an ACS and CAE in a single center in Mexico City, two groups were observed based on the treatment at discharge: dual antiplatelet therapy (group 1) and anticoagulation with either a VKA or a DOAC, regardless of antiplatelet therapy (group 2). The main outcome was MACE, which was a composite of all-cause mortality, reinfarction, and ischemic stroke at 4.5 years follow-up. Results: A total of 354 patients admitted for ACS and CAE were included. 228 (64.4%) patients were classified in the DAPT group and 126 (35.5%) in the anticoagulants group. The DAPT group had higher type 2 diabetes rates, NSTEMI presentation, and lower-grade ectasia. The anticoagulation group had higher STEMI presentation and higher-grade ectasia. The DAPT group had 33 (14.5%) events of MACE, whereas the anticoagulation group had 16 (13.1%) events. Anticoagulants were not associated with a risk reduction of the primary endpoint (HR 0.95; 95% CI, 0.47–1.54; p = 0.59), nor any of the individual components. Conclusion: This retrospective cohort study showed similar effectiveness between DAPT and anticoagulation in patients with ACS and CAE for preventing MACE, and lower bleeding risk. Further research is needed to identify optimal candidates for each antithrombotic regime. Graphical DAPT: double antiplatelet therapy, HR: hazard ratio
- Open Access
- 18 June 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (6) , 1493
Serum NT-ProBNP/Chloride Ratio Predicts Adverse Cardiovascular Outcomes in Patients with Acute Heart Failure
Background: Heart failure (HF) is a public health issue. It represents the second most common cause of hospitalization and the leading cause in individuals over 60 years old. Tools that predict adverse outcomes in patients with HF are needed. Objective: This study analyzed the prognostic role of the serum NT-proBNP/chloride ratio as a predictor of major cardiovascular events in patients with acute decompensated HF. Methods: Patients with a confirmed diagnosis of acute decompensated heart failure were retrospectively enrolled in the study; admission NT-proBNP/chloride ratio was used to stratify patients above or below the median (>/p = 0.0015) of the primary endpoint. After multivariate analysis, only serum NT-proBNP/chloride ratio (p = 0.02) and diastolic pressure (0.037) remained significant. The area under the ROC curve for the NT-proBNP/chloride ratio for predicting the primary composite endpoint was significantly superior when compared with AUC for NT-proBNP or chloride alone. Conclusions: The serum NT-proBNP/chloride ratio is a novel, easy to use predictor of short- and medium-term cardiovascular events in patients with acute decompensated HF.
- 18 June 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (6) , 1493
Open AccessSerum NT-ProBNP/Chloride Ratio Predicts Adverse Cardiovascular Outcomes in Patients with Acute Heart Failure
Background: Heart failure (HF) is a public health issue. It represents the second most common cause of hospitalization and the leading cause in individuals over 60 years old. Tools that predict adverse outcomes in patients with HF are needed. Objective: This study analyzed the prognostic role of the serum NT-proBNP/chloride ratio as a predictor of major cardiovascular events in patients with acute decompensated HF. Methods: Patients with a confirmed diagnosis of acute decompensated heart failure were retrospectively enrolled in the study; admission NT-proBNP/chloride ratio was used to stratify patients above or below the median (>/p = 0.0015) of the primary endpoint. After multivariate analysis, only serum NT-proBNP/chloride ratio (p = 0.02) and diastolic pressure (0.037) remained significant. The area under the ROC curve for the NT-proBNP/chloride ratio for predicting the primary composite endpoint was significantly superior when compared with AUC for NT-proBNP or chloride alone. Conclusions: The serum NT-proBNP/chloride ratio is a novel, easy to use predictor of short- and medium-term cardiovascular events in patients with acute decompensated HF.
- Open Access
- 9 January 2025
- Published by Ubiquity Press, Ltd. in Global Heart
- Vol. 20 (1) , 78
Sex Disparities in Cardiogenic Shock: Risk Factors, Treatment Intensity, and Mortality in a Single Latin American Country
Background: Cardiogenic shock (CS) carries a high in-hospital mortality, with limited data on sex-related disparities in Latin America. Women remain underrepresented in CS studies. Objectives: To evaluate sex-specific differences in characteristics, management, and mortality in acute myocardial infarction–related (AMI-CS) and non-AMI-CS in a large Latin-American cohort. Methods: We retrospectively analyzed 9430 patients (5016 AMI-CS and 4414 non-AMI-CS) with SCAI-CSWG stages B–E in a reference center in Mexico City from 2005 to 2023. The primary outcome was in-hospital mortality. Analyses included multivariable Cox models and propensity score matching (PSM). Results: Women with AMI-CS were older (67 vs. 60 years), had more hypertension (66% vs. 52%) and diabetes (53% vs. 38%), and received less primary reperfusion (62% vs. 71%) and mechanical circulatory support (11.6% vs. 14.7%) than men (all P < 0.05). In non-AMI-CS, women were older (66 vs. 60 years), had more prior heart failure (33% vs. 24%), while men had more chronic obstructive pulmonary disease (COPD) and prior MI (all P < 0.05). Unadjusted mortality was higher in women in AMI-CS (24.6% vs. 16.3%, HR 1.48, 95% CI 1.28–1.72) and non-AMI-CS (HR 1.18, 95% CI 1.05–1.32). After PSM, mortality differences were not significant in AMI-CS (HR 1.22, 95% CI 1.00–1.48) or non-AMI-CS (HR 1.07, 95% CI 0.92–1.24). Conclusions: Women with CS in Latin America present with greater comorbidity and less aggressive/invasive management. While unadjusted mortality was higher in women, these differences were no longer significant after PSM, indicating that baseline factors and treatment disparities largely explain excess risk.
- 9 January 2025
- Published by Ubiquity Press, Ltd. in Global Heart
- Vol. 20 (1) , 78
Open AccessSex Disparities in Cardiogenic Shock: Risk Factors, Treatment Intensity, and Mortality in a Single Latin American Country
Background: Cardiogenic shock (CS) carries a high in-hospital mortality, with limited data on sex-related disparities in Latin America. Women remain underrepresented in CS studies. Objectives: To evaluate sex-specific differences in characteristics, management, and mortality in acute myocardial infarction–related (AMI-CS) and non-AMI-CS in a large Latin-American cohort. Methods: We retrospectively analyzed 9430 patients (5016 AMI-CS and 4414 non-AMI-CS) with SCAI-CSWG stages B–E in a reference center in Mexico City from 2005 to 2023. The primary outcome was in-hospital mortality. Analyses included multivariable Cox models and propensity score matching (PSM). Results: Women with AMI-CS were older (67 vs. 60 years), had more hypertension (66% vs. 52%) and diabetes (53% vs. 38%), and received less primary reperfusion (62% vs. 71%) and mechanical circulatory support (11.6% vs. 14.7%) than men (all P < 0.05). In non-AMI-CS, women were older (66 vs. 60 years), had more prior heart failure (33% vs. 24%), while men had more chronic obstructive pulmonary disease (COPD) and prior MI (all P < 0.05). Unadjusted mortality was higher in women in AMI-CS (24.6% vs. 16.3%, HR 1.48, 95% CI 1.28–1.72) and non-AMI-CS (HR 1.18, 95% CI 1.05–1.32). After PSM, mortality differences were not significant in AMI-CS (HR 1.22, 95% CI 1.00–1.48) or non-AMI-CS (HR 1.07, 95% CI 0.92–1.24). Conclusions: Women with CS in Latin America present with greater comorbidity and less aggressive/invasive management. While unadjusted mortality was higher in women, these differences were no longer significant after PSM, indicating that baseline factors and treatment disparities largely explain excess risk.
- Open Access
- 4 November 2024
- Published by Oxford University Press (OUP) in European Heart Journal: Acute Cardiovascular Care
- Vol. 13 (12) , 852-853
Answer: An unusual presentation of acute myocardial infarction
This Spot the Diagnosis article refers to ‘Question: an unusual presentation of acute myocardial infarction’, by B.Á. Díaz-Herrera et al. doi:10.1093/ehjacc/zuae081.
- 4 November 2024
- Published by Oxford University Press (OUP) in European Heart Journal: Acute Cardiovascular Care
- Vol. 13 (12) , 852-853
Open AccessAnswer: An unusual presentation of acute myocardial infarction
This Spot the Diagnosis article refers to ‘Question: an unusual presentation of acute myocardial infarction’, by B.Á. Díaz-Herrera et al. doi:10.1093/ehjacc/zuae081.
- 28 October 2024
- Published by Oxford University Press (OUP) in European Heart Journal: Acute Cardiovascular Care
- Vol. 13 (12) , 851
Question: An unusual presentation of acute myocardial infarction
- 28 October 2024
- Published by Oxford University Press (OUP) in European Heart Journal: Acute Cardiovascular Care
- Vol. 13 (12) , 851
Question: An unusual presentation of acute myocardial infarction
- Open Access
- 17 July 2024
- Published by Instituto Mexicano del Seguro Social in Archivos de Cardiología de México
- Vol. 94 (3) , 269-275
Desacoplamiento mecánico y eléctrico: el papel de la resonancia magnética cardiaca en la miocardiopatía arritmogénica. Prueba de concepto
Objetivos: La miocardiopatía arritmogénica (MCA) es un trastorno cardíaco complejo asociado con arritmias ventriculares (AV). Comprender...
- 17 July 2024
- Published by Instituto Mexicano del Seguro Social in Archivos de Cardiología de México
- Vol. 94 (3) , 269-275
Open AccessDesacoplamiento mecánico y eléctrico: el papel de la resonancia magnética cardiaca en la miocardiopatía arritmogénica. Prueba de concepto
Objetivos: La miocardiopatía arritmogénica (MCA) es un trastorno cardíaco complejo asociado con arritmias ventriculares (AV). Comprender...